Compare Diamondback Energy Inc (FANG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Organon & Co. Common Stock — how do they compare? Diamondback Energy Inc trades at $197.66 (market cap $55.31B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Diamondback Energy Inc is far larger — about 15.3× Organon & Co. Common Stock's market cap, and Diamondback Energy Inc pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 70 Days and Organon & Co. Common Stock for 0 Days on average.
| FANG | OGN | |
|---|---|---|
Market Cap | $55.31B | $3.61B |
Volume | 2,808,399 | 1,808,049 |
Sector | Energy | Health |
52-Week High | $213.69 | $13.81 |
52-Week Low | $137.29 | $5.70 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $67.46B | $11.03B |
Dividend Yield | 2.23% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $198.18, up 1.57% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with recent quarterly beats and solid revenue growth from $14.93B in 2025 to projected $17.0B in 2026. Technical indicators show bullish moving averages while RSI levels suggest potential overbought conditions. The company maintains strong cash flow generation with $8.76B from operations in 2025 and recently announced a $1.10 dividend payment.
FANG presents a compelling growth opportunity with 90% analyst buy ratings and a $233.79 consensus price target offering 18% upside. However, declining profit margins from 45.84% in 2022 to 11.14% in 2025 and elevated P/E ratio of 37.75 warrant caution. Oil price volatility and insider selling activity represent key risks for investors considering entry at current levels near recent highs.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
